banner
发布时间：2019-07-09 00:00:00
全部分类
论文
- 分类：科学研究
- 发布时间：2019-05-29 00:00:00
- 访问量：0
概要:
详情
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cellmalignancies.
Wang N1,2, Hu X1,2, Cao W1,2, Li C1,2, Xiao Y1,2, Cao Y1,2, Gu C3,4, Zhang S4, Chen L1,2, Cheng J1,2, Wang G1,2, Zhou X1,2, Zheng M1,2, Mao X1,2,Jiang L1,2, Wang D1,2, Wang Q1,2, Lou Y1,2, Cai H1,2, Yan D5, Zhang Y1,2, Zhang T3,4, Zhou J1,2, Huang L1,2.
Blood. 2020 Jan 2;135(1):17-27. doi: 10.1182/blood.2019000017.
Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients.
Wang D1, Zeng C1, Xu B1, Xu JH1, Wang J1, Jiang LJ1, Wang QX1, Li CR1, Wang N1, Huang L1, Zhang YC1, Xiao Y2, Zhou JF3.
Blood Cancer J. 2020 Jan 23;10(1):8. doi: 10.1038/s41408-020-0274-9.
Entecavir Prophylaxis for Hepatitis B Virus Reactivation in Patients with CAR T-cell Therapy.
Cao W1, Wei J2, Wang N3, Xu H4, Xiao M5, Huang L4, Cao Y1, Li C1, Xiao Y1, Gu C6, Zhang S6, Li D1, Zhang Y5, Zhang T7, Zhou J5, Huang L5.
Blood. 2020 Apr 14. pii: blood.2020004907. doi: 10.1182/blood.2020004907.
Efficacy and Toxicity for CD22/CD19 Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed/Refractory Aggressive B-cell Lymphoma Involving the Gastrointestinal Tract
Chen Zeng 1, Jiali Cheng 1, Tongjuan Li 1, Jin Huang 1, Chunrui Li 1, Lijun Jiang 1, Jue Wang 1, Liting Chen 1, Xia Mao 1, Li Zhu 1, Yaoyao Lou 1, Jianfeng Zhou 1, Xiaoxi Zhou 2
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13
Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
扫二维码用手机看
